Abstract 3280
Background
Cardiovascular events are an important cause of mortality in patients cured of colorectal cancer and are also potential complications of new therapies for metastatic CRC. The American Heart Association’s “Simple 7” offers a practical public health conceptualization of cardiovascular health. They include healthy behaviours: non-smoking, active physical activity (MVPA > 150 min/w), healthy diet and low body mass index (BMI); and health factors: no hypertension, no diabetes, no hypercholesterolemia. Whereas factors are non-modifiable, behaviours can be changed. Studies have shown that prevalence of ideal cardiovascular health in the US is only 0.1%.
Methods
Patients with a recent diagnosis of CRC who accepted to participate were prospectively evaluated. BMI, blood pressure, glucose and cholesterol were measured at the hospital. Physical activity was objectively evaluated with accelerometers. Adherence to a healthy diet was evaluated through the PREDIMED (adherence to Mediterranean diet) questionnaire. Information about smoking and past cardiovascular disease or risk factors was obtained from the clinical record.
Results
91 patients were recruited between March 15 and March 17. 36% were metastatic. Age 65 (25-81), 69% male 31% female, BMI 26.2 ±3.6, Waist 95,6 ±12 cm, mean MVPA 350±248 min/wk, mean sedentarism 3394±1123. 9% had a history of CV disease (ischemic, cerebrovascular, heart failure). 34% were classified as high CV risk. Only one patient showed an ICVH.rnTable:
1601P
rn| rn | Healthy behaviours | rnHealth Factors | rn||||||
|---|---|---|---|---|---|---|---|---|
| ICVH | No CV history | Nonsmoking | BMI ConclusionsThe prevalence of ICVH in a population of Spanish CRC patients was 1%. This population was overall compliant with PA recommendations, adhered to a healthy diet and less than 10% smoke in the last year. Hypertension was the most prevalent risk factor. Overweight was the most prevalent unhealthy behaviour. Interventions should be aimed at reducing BMI. Interventions exploring programs with vigorous physical activity and diet modifications in CRC survivors are warranted. Clinical trial identificationLegal entity responsible for the studyAna Ruiz-Casado FundingNone DisclosureAll authors have declared no conflicts of interest. Resources from the same session3673 - Phase II randomized trial of capecitabine + radiation therapy with/ without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival.Presenter: Cristina Gravalos Session: Poster display session Resources: Abstract 2418 - Immunological features of resected tumor after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT) become the superior prediction markers for recurrence in rectal cancer.Presenter: Ken Imaizumi Session: Poster display session Resources: Abstract 2581 - The ADC value of post-RT might predict TRG after neoadjuvant radiotherapy for local advanced rectal cancerPresenter: Wu Junxin Session: Poster display session Resources: Abstract 3513 - Polyethylene Glycol embolics loaded with irinotecan for chemoembolization of refractory liver metastases from colorectal cancerPresenter: Giammaria Fiorentini Session: Poster display session Resources: Abstract 4702 - Neoadjuvant Systemic Chemotherapy prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the treatment of Peritoneal Carcinomatosis from Colorectal CancerPresenter: Nethanel Asher Session: Poster display session Resources: Abstract 3843 - Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): final results from an international trial (EORTC 05011)Presenter: Carlo Garufi Session: Poster display session Resources: Abstract 4961 - A multicentre, randomized phase 3 study on the optimization of the combination of bevacizumab with mFOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC)Presenter: Antonio Avallone Session: Poster display session Resources: Abstract 5518 - First-in-Human Phase I Study of Bacterial RNA Interference Therapeutic CEQ508 in Patients with Familial Adenomatous Polyposis (FAP)Presenter: Vuong Trieu Session: Poster display session Resources: Abstract 3024 - A Multicentre Phase I/II Study of TAS-102 with Nintedanib in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (N-TASK FORCE: EPOC1410)Presenter: Kentaro Yamazaki Session: Poster display session Resources: Abstract 3654 - BEACON CRC: Safety Lead-In (SLI) for the Combination of Binimetinib (BINI), Encorafenib (ENCO), and Cetuximab (CTX) in Patients (Pts) with BRAF-V600E Metastatic Colorectal Cancer (mCRC)Presenter: Sanne Huijberts Session: Poster display session Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||||